Compare Schwab US Dividend Equity ETF (SCHD) vs 10X Genomics Inc (TXG) Price & Performance

SCHD trades at $33.06, up 1.26% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 in 2026, with recent news highlighting its dividend growth and defensive positioning. Key support sits at $32 with resistance at $34, while oscillators show neutral momentum. The fund's rules-based approach focuses on high-quality dividend stocks, though recent exclusions like Broadcom have sparked discussion about opportunity costs.

SCHD offers income investors exposure to rising dividends with lower fees, but faces headwinds from interest rate sensitivity and strict selection criteria that may limit growth participation. The current pullback from August highs near $35 presents a potential entry point for dividend-focused portfolios seeking quality and yield sustainability amid market volatility.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.